PMID- 37731737 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230922 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 14 DP - 2023 TI - Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. PG - 1234342 LID - 10.3389/fphar.2023.1234342 [doi] LID - 1234342 AB - Background: Systemic chemotherapy (SC) remains the only first-line treatment for unresectable intrahepatic cholangiocarcinoma (iCCA). Hepatic arterial infusion chemotherapy (HAIC) has been recently proven to be effective in managing hepatocellular carcinoma (HCC). Hence, our study aims to investigate the safety and efficacy of HAIC in treating unresectable iCCA patients. Methods: We reviewed 146 patients with unresectable iCCA who had received HAIC or SC between March 2016 and March 2022 in a retrospective manner. Outcomes of patients and safety were compared between the HAIC and SC groups. Results: There were 75 and 71 patients in the HAIC and SC groups, respectively. The median OS in the HAIC and SC groups was 18.0 and 17.8 months (p = 0.84), respectively. The median PFS in the HAIC and SC groups was 10.8 and 11.4 months (p = 0.59), respectively. However, the HAIC group had significantly longer intrahepatic progression-free survival (IPFS) than the SC group (p = 0.035). The median IPFS in the HAIC and SC groups was 13.7 and 11.4 months, respectively. According to the OS (p = 0.047) and PFS (p = 0.009), single-tumor patients in the HAIC group appeared to benefit more. In addition, the overall incidence of adverse events (AEs) was lower in the HAIC group than that in the SC group. Conclusion: Our study revealed that HAIC was a safe and effective therapeutic regimen for unresectable iCCA with better intrahepatic tumor control when compared to SC. Meanwhile, patients with single tumor were more likely to benefit from HAIC than SC. CI - Copyright (c) 2023 Yang, Fu, Wu, Hu, Pan, Wang, Chen, Hu, Zhou, Chen and Zhang. FAU - Yang, Zhenyun AU - Yang Z AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Fu, Yizhen AU - Fu Y AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Wu, Weijie AU - Wu W AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Hu, Zili AU - Hu Z AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Pan, Yangxun AU - Pan Y AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Wang, Juncheng AU - Wang J AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Chen, Jinbin AU - Chen J AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Hu, Dandan AU - Hu D AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Zhou, Zhongguo AU - Zhou Z AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Chen, Minshan AU - Chen M AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. FAU - Zhang, Yaojun AU - Zhang Y AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. AD - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. LA - eng PT - Journal Article DEP - 20230905 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC10508288 OTO - NOTNLM OT - adverse events OT - hepatic arterial infusion chemotherapy OT - intrahepatic cholangiocarcinoma OT - overall survival OT - progression-free survival OT - systemic chemotherapy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/09/21 06:42 MHDA- 2023/09/21 06:43 PMCR- 2023/09/05 CRDT- 2023/09/21 04:03 PHST- 2023/06/04 00:00 [received] PHST- 2023/08/21 00:00 [accepted] PHST- 2023/09/21 06:43 [medline] PHST- 2023/09/21 06:42 [pubmed] PHST- 2023/09/21 04:03 [entrez] PHST- 2023/09/05 00:00 [pmc-release] AID - 1234342 [pii] AID - 10.3389/fphar.2023.1234342 [doi] PST - epublish SO - Front Pharmacol. 2023 Sep 5;14:1234342. doi: 10.3389/fphar.2023.1234342. eCollection 2023.